

Minutes
Drug Allergy GDG 1
Location: National Clinical Guidelines Centre
5th Floor, 180 Great Portland Street, London, W1W 5QZ
Friday 14th December, 2012, 1000 – 1600

Attendees

GDG

Shuaib Nasser
Alice Osborne
David Cousins
James Larcombe
Mandy East
Mike Arden-Jones
Nicola Mundy
Paul Whitaker
Pamela Ewan

GDG Apologies:

George Du Toit
Andrew Williams

NICE

Barbara Meredith
Oliver Bailey
Rachel Ryle

NCGC

Carlos Sharpin
Kate Kelley
Kathy De Mott
Lee Yee Chong
Margaret Constanti
Tamara Diaz
Vicki Pollit

-
1. Welcome, introductions and apologies:
The Chair welcomed all to the first Drug Allergy GDG meeting, led introductions, and announced formal apologies for George Du Toit and Andrew Williams.
 2. Declarations of interest:
The chair invited group members to declare interests related to the days agenda. Pam Ewan submitted one declaration related to her husband's work as a consultant for GSK.
 3. The chair provided an overview of the agenda.
 4. The following presentations were delivered to the Guideline Development Group, providing an induction to the role of Group members, the National Clinical Guideline Centre's core team, the National Institute for Health and Clinical Excellence, and Patient/Carer Representatives. The GDG was also introduced to the Scope of the Guideline, and how Health Economics, Information Science and Research methods will be used throughout development.
 - 4.1. Presentation 1 Working with NICE – Rachel Ryle
 - 4.2. Presentation 2 Patient and carer involvement in the guideline process – Barbara Meredith
 - 4.3. Presentation 3 Scope of the guideline – Shuaib Nasser
 - 4.4. Presentation 4 Health economics – Margaret Constanti
 - 4.5. Presentation 5 Searching for and Reviewing the evidence – Lee Yee Chong/Carlos Sharpin
 5. Survey Results: The group had been asked to participate in a survey to comment on a draft list of the most important clinical issues for the guideline. Results of this survey were presented by Kathy De Mott. The group was reminded of the five key areas identified in the scope of the guideline and meeting discussions would help to further clarify the most important clinical issues for each topic.
 6. Close of business: There being no further business the meeting ended at 4:00 p.m. the next meeting of the drug allergy guideline development group will take place at the NCGC's Offices, on 25th January 2013.